Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 129

1.
2.

Phase II evaluation of liposomal doxorubicin (Doxil) in recurrent or advanced leiomyosarcoma of the uterus: a Gynecologic Oncology Group study.

Sutton G, Blessing J, Hanjani P, Kramer P; Gynecologic Oncology Group..

Gynecol Oncol. 2005 Mar;96(3):749-52.

PMID:
15721421
3.

Phase II trial of ifosfamide and mesna in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study.

Sutton GP, Blessing JA, Barrett RJ, McGehee R.

Am J Obstet Gynecol. 1992 Feb;166(2):556-9.

PMID:
1536229
4.

A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: A Gynecologic Oncology Group Study.

Sutton G, Brunetto VL, Kilgore L, Soper JT, McGehee R, Olt G, Lentz SS, Sorosky J, Hsiu JG.

Gynecol Oncol. 2000 Nov;79(2):147-53.

PMID:
11063636
5.

Phase II trial of ifosfamide and mesna in mixed mesodermal tumors of the uterus (a Gynecologic Oncology Group study).

Sutton GP, Blessing JA, Rosenshein N, Photopulos G, DiSaia PJ.

Am J Obstet Gynecol. 1989 Aug;161(2):309-12.

PMID:
2548382
6.

Sequential dose-dense doxorubicin and ifosfamide for advanced soft tissue sarcomas: a Phase II trial by the Spanish Group for Research on Sarcomas (GEIS).

Maurel J, Fra J, López-Pousa A, García del Muro X, Balañá C, Casado A, Martín J, Martínez-Trufero J, de las Peñas R, Buesa JM; Spanish Group for Research on Sarcomas (GEIS)..

Cancer. 2004 Apr 1;100(7):1498-506.

7.

Ifosfamide with and without adriamycin in advanced uterine leiomyosarcoma.

Hawkins RE, Wiltshaw E, Mansi JL.

Cancer Chemother Pharmacol. 1990;26 Suppl:S26-9.

PMID:
2347045
8.

Treatment of metastatic uterine leiomyosarcoma with cisplatin, pirarubicin, and ifosfamide.

Hirota Y, Miyamura K, Hayata T, Miyakawa I.

Gynecol Obstet Invest. 1997;44(1):70-2.

PMID:
9251960
9.

A phase II Gynecologic Oncology Group trial of ifosfamide and mesna in advanced or recurrent adenocarcinoma of the endometrium.

Sutton GP, Blessing JA, DeMars LR, Moore D, Burke TW, Grendys EC.

Gynecol Oncol. 1996 Oct;63(1):25-7.

PMID:
8898163
10.

Study of either ifosfamide or teniposide compared to a standard chemotherapy for extensive disease small cell lung cancer: an Eastern Cooperative Oncology Group randomized study (E1588).

Ettinger DS, Finkelstein DM, Ritch PS, Lincoln ST, Blum RH; Eastern Cooperative Oncology Group..

Lung Cancer. 2002 Sep;37(3):311-8.

PMID:
12234701
11.

Gynecologic Oncology Group experience with ifosfamide.

Sutton GP, Blessing JA, Photopulos G, Berman ML, Homesley HD.

Semin Oncol. 1990 Apr;17(2 Suppl 4):6-10.

PMID:
2159188
12.
14.

Phase II study of ifosfamide and mesna in refractory adenocarcinoma of the endometrium. A Gynecologic Oncology Group study.

Sutton GP, Blessing JA, Homesley HD, McGuire WP, Adcock L.

Cancer. 1994 Mar 1;73(5):1453-5.

15.

Cisplatin-based chemotherapy regimen (DECAV) for uterine sarcomas.

Pautier P, Genestie C, Fizazi K, Morice P, Mottet C, Haie-Meder C, Le Cesne A, Lhommé C.

Int J Gynecol Cancer. 2002 Nov-Dec;12(6):749-54.

PMID:
12445254
16.

Phase II study of mitomycin, doxorubicin, and cisplatin in the treatment of advanced uterine leiomyosarcoma: a Gynecologic Oncology Group study.

Edmonson JH, Blessing JA, Cosin JA, Miller DS, Cohn DE, Rotmensch J.

Gynecol Oncol. 2002 Jun;85(3):507-10.

PMID:
12051882
17.
19.

Phase II experience with ifosfamide/mesna in gynecologic malignancies: preliminary report of Gynecologic Oncology Group studies.

Sutton GP, Blessing JA, Photopulos G, Berman ML, Homesley HD.

Semin Oncol. 1989 Feb;16(1 Suppl 3):68-72.

PMID:
2539647
20.

Adjuvant ifosfamide and cisplatin in patients with completely resected stage I or II carcinosarcomas (mixed mesodermal tumors) of the uterus: a Gynecologic Oncology Group study.

Sutton G, Kauderer J, Carson LF, Lentz SS, Whitney CW, Gallion H; Gynecologic Oncology Group..

Gynecol Oncol. 2005 Mar;96(3):630-4.

PMID:
15721404

Supplemental Content

Support Center